Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017" report to their offering.

Acute Respiratory Distress Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 3, 2, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Acute Respiratory Distress Syndrome Overview
  3. Therapeutics Development
  4. Pipeline Products for Acute Respiratory Distress Syndrome - Overview
  5. Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis
  6. Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies
  7. Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes
  8. Acute Respiratory Distress Syndrome Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Acute Respiratory Distress Syndrome - Products under Development by Companies
  13. Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes
  14. Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
  • Altor BioScience Corp
  • Athersys Inc
  • Commence Bio Inc
  • Faron Pharmaceuticals Oy
  • GlaxoSmithKline Plc
  • Global Blood Therapeutics Inc
  • Hydra Biosciences Inc
  • Implicit Bioscience Ltd
  • Phylogica Ltd
  • Savara Inc
  • Silence Therapeutics Plc

For more information about this report visit http://www.researchandmarkets.com/research/7jf9rp/acute_respiratory

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs